High phosphorous intake associated with increased risk of lethal prostate cancer
the ONA take:
According to a new study published in the American Journal of Clinical Nutrition, phosphorous is independently associated with the risk of developing lethal and high-grade prostate cancer.
Researchers identified nearly 48,000 men who reported their diet in 1986 and every 4 years thereafter. During the 24-year follow-up, 5,861 participants developed prostate cancer, 789 of which were lethal cancers. Results showed phosphorous intake was linked with a greater risk for developing prostate cancer, including lethal and high-grade disease.
This association was independent of calcium and dairy, fish, red meat, and white meat intake. In addition, high calcium intake was associated with an elevated risk for developing advanced-stage and high-grade disease 12 to 16 years after exposure.
High phosphorous intake was linked with an increased risk for developing advanced-stage and high-grade prostate cancer 0 to 8 years after exposure. Foods high in phosphorous include: seeds, lentils, cheese, colas, shellfish, and yogurt.
Phosphorous is independently associated with the risk of developing lethal and high-grade prostate cancer.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|